Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

BioNTech SE

BNTX
Current price
98.74 USD +0.14 USD (+0.14%)
Last closed 99.91 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 23 833 239 552 USD
Yield for 12 month -38.91 %
Week
Month
Year
BNTX
21.11.2021 - 28.11.2021

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany. Address: An der Goldgrube 12, Mainz, Germany, 55131

Analytics

WallStreet Target Price

139.13 USD

P/E ratio

5.2206

Dividend Yield

1.32 %

Current Year

+18 845 571 825 USD

Last Year

+20 659 408 851 USD

Current Quarter

+974 688 368 USD

Last Quarter

+182 570 355 USD

Current Year

+13 911 708 671 USD

Last Year

+16 456 371 455 USD

Current Quarter

+256 491 209 USD

Last Quarter

-401 284 633 USD

Key Figures BNTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 5 939 800 064 USD
Operating Margin TTM -293.44 %
PE Ratio 5.2206
Return On Assets TTM 16.92 %
PEG Ratio 0.0449
Return On Equity TTM 23.82 %
Wall Street Target Price 139.13 USD
Revenue TTM 9 184 199 680 USD
Book Value 83.02 USD
Revenue Per Share TTM 37.94 USD
Dividend Share
Quarterly Revenue Growth YOY -94.8 %
Dividend Yield 1.32 %
Gross Profit TTM 16 065 200 000 USD
Earnings Share 19.04 USD
Diluted Eps TTM 19.04 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -85.6 %
Profit Margin 47.64 %

Dividend Analytics BNTX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BNTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 2.11
Ex Dividend Date 02.06.2022
Forward Annual Dividend Yield 1.32 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date 17.06.2022

Stock Valuation BNTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 5.2206
Forward PE 34.0136
Enterprise Value Revenue 0.729
Price Sales TTM 2.595
Enterprise Value EBITDA 1.1074
Price Book MRQ 1.092

Financials BNTX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BNTX

For 52 weeks

88 USD 188.99 USD
50 Day MA 100.37 USD
Shares Short Prior Month 3 261 238
200 Day MA 111.86 USD
Short Ratio 4.72
Shares Short 2 657 655
Short Percent 3.04 %